Anti-VEGF agents in metastatic colorectal cancer (mCRC): Are they all alike?

Cancer Management and Research

Volumn 5, Issue 1, 2013, Pages 103-115

  Saif, Muhammad Wasif ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aflibercept; Antiangiogenesis; Metastatic colorectal cancer (mCRC); Tyrosine kinase inhibitor (TKI); Vascular endothelial growth factor (VEGF)

Indexed keywords

AFLIBERCEPT; AXITINIB; BEVACIZUMAB; BRIVANIB; CEDIRANIB; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; ICRUCUMAB; IMC 1121 C; IRINOTECAN; LUCIFERASE; NINTEDANIB; OXALIPLATIN; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RAMUCIRUMAB; REGORAFENIB; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ABDOMINAL PAIN; ANGIOGENESIS; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ASTHENIA; BLEEDING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DYSPHONIA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; GLIOBLASTOMA; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; INFECTION; LEUKOPENIA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MEDLINE; METASTATIC COLORECTAL CANCER; MOUTH ULCER; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; PROTEIN TARGETING; PROTEINURIA; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS; WEIGHT REDUCTION;

EID: 84879153063     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S45193     Document Type: Review

References (84)

1. Folkman J, Klagsbrun M. Angiogenic factors. Science. 1987;235(4787): 442-447.
2. Samant RS, Shevde LA. Recent advances in anti-angiogenic therapy of cancer. Oncotarget. 2011;2(3):122-134.
3. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist. 2004;9 Suppl 1:2-10.
4. Takahashi S. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull. 2011;34(12):1785-1788.
5. Crawford Y, Ferrara N. VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res. 2009;335(1):261-269.
6. Cao Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal. 2009;2(59):re1.
7. Escudero-Esparza A, Martin TA, Davies ML, Jiang WG. PGF isoforms, PlGF-1 and PlGF-2, in colorectal cancer and the prognostic signifcance. Cancer Genomics Proteomics. 2009;6(4):239-246.
8. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298-307.
9. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333(2):328-335.
10. Hurwitz H, Fehrenbacher L, Novotny W. Bevacizumab plus irinotecan, fuorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342.
11. Chu E. An update on the current and emerging targeted agents in meta-static colorectal cancer. Clin Colorectal Cancer. 2012;11(1):1-13.
12. Li X, Lee C, Tang Z, et al. VEGF-B: a survival, or an angiogenic factor? Cell Adh Migr. 2009;3(4):322-327.
13. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001;7(5):575-583.
14. Kopetz S, Hoff PM, Morris JS, et al. Phase II trial of infusional fuorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010;28(3):453-459.
15. Korpanty G, Sullivan LA, Smyth E, Carney DN, Brekken RA. Molecular and clinical aspects of targeting the VEGF pathway in tumors. J Oncol. 2010;2010:652320.
16. Olofsson B, Korpelainen E, Pepper MS, et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A. 1998;95(20):11709-11714.
17. Ribatti D. The discovery of the placental growth factor and its role in angiogenesis: a historical review. Angiogenesis. 2008;11(3):215-221.
18. Hilmi C, Guyot M, Pagès G. VEGF spliced variants: possible role of anti-angiogenesis therapy. J Nucleic Acids. 2012;2012:162692.
19. Chu QS. Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin Biol Ther. 2009;9(2):263-271.
20. Olofsson B, Pajusola K, von Euler G, Chilov D, Alitalo K, Eriksson U. Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform. J Biol Chem. 1996;271(32):19310-19317.
21. Fischer C, Mazzone M, Jonckx B, Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer. 2008;8(12):942-956.
22. Hamerlik P, Lathia JD, Rasmussen R, et al. Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med. 2012;209(3):507-520.
23. Van de Veire S, Stalmans I, Heindryckx F, et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell. 2010;141(1):178-190.
24. Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell. 2007;131(3):463-475.
25. Bais C, Wu X, Yao J, et al. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell. 2010;141(1):166-177.
26. Loges S, Schmidt T, Carmeliet P. Antimyeloangiogenic therapy for cancer by inhibiting PlGF. Clin Cancer Res. 2009;15(11):3648-3653.
27. Ya o J, Wu X, Zhuang G, et al. Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc Natl Acad Sci U S A. 2011;108(28):11590-11595.
28. Zhang F, Tang Z, Hou X, et al. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci U S A. 2009;106(15): 6152-6157.
29. Tol J, Punk CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther. 2010;32(3):437-453.
30. Avastin® (bevacizumab) [prescribing information]. South San Francisco, CA: Genentech, Inc; 2013.
31. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58-62.
32. Van der Veldt AA, Lubberink M, Bahce I, et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell. 2012; 21(1):82-91.
33. Maitland ML, Lou XJ, Ramirez J, et al. Vascular endothelial growth factor pathway. Pharmacogenet Genomics. 2010;20(5):346-349.
34. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007; 8(8):610-622.
35. Keunen O, Johansson M, Oudin A, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A. 2011;108(9):3749-3754.
36. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99(17): 11393-11398.
37. Tew W P, Gordon M, Murren J, et al. Phase 1study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin Cancer Res. 2010;16(1):358-366.
38. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2): 171-185.
39. Teng LS, Jin KT, He KF, Zhang J, Wang HH, Cao J. Clinical applications of VEGF-trap (aflibercept) in cancer treatment. J Chin Med Assoc. 2010;73(9):449-456.
40. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fuorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30(28):3499-3506.
41. ZALTRAP® (ziv-aflibercept) [prescribing information]. Bridgewater, NJ: Regeneron Pharmaceuticals, Inc/sanof-aventis US LLC; 2012.
42. Sanof. A Multinational, randomized, double-blind study, comparing the efficacy of aflibercept once every 2 weeks versus placebo in patients treated with gemcitabine for metastatic pancreatic cancer (VANILLA). In: Clini-calTrials.gov [website on the internet]. Bethesda, MD: US National Library of Medicine; 2012. Available from: http://www.clinicaltrials.gov/ct2/show/ NCT00574275. NLM identifer: NCT00574275. Accessed April 26, 2013.
43. Sanof. A multicenter, randomized, double blind study comparing the efficacy and safety of aflibercept versus placebo administered every 3 weeks in patients treated with docetaxel/prednisone for metastatic androgen-independent prostate cancer (VENICE). In: ClinicalTrials.gov [website on the internet]. Bethesda, MD: US National Library of Medicine; 2012. Available from: http://clinicaltrials.gov/show/NCT00519285. NLM identifer: NCT00519285. Accessed April 26, 2013.
44. Sanof. A multinational, randomized, double-blind study comparing aflibercept versus placebo in patients treated with second-line docetaxel after failure of one platinum based therapy for locally advanced or meta-static non-small-cell lung cancer (VITAL). In: ClinicalTrials.gov [website on the internet]. Bethesda, MD: US National Library of Medicine; 2012. Available from: http://clinicaltrials.gov/show/NCT00532155. NLM identifer: NCT00532155. Accessed April 26, 2013.
45. Sanof-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer [webpage on the Internet]. PR Newswire; March 10, 2011. Available from: http://www.prnewswire.com/news-releases/ sanof-aventis-and-regeneron-report-top-line-results-from-phase-iii-study-with-aflibercept-vegf-trap-in-second-line-non-small-cell-lung-cancer-117757228.html. Accessed November 30, 2012.
46. Jin K, Shen Y, He K, Xu Z, Li G, Teng L. Aflibercept (VEGF Trap): one more double edged sword of anti-VEGF therapy for cancer? Clin Transl Oncol. 2010;12(8):526-532.
47. Spratlin J. Ramucirumab (IMC-1121B): monoclonal antibody inhibition of vascular endothelial growth factor receptor-2. Curr Oncol Rep. 2011;13(2):97-102.
48. Krupitskaya Y, Wakelee HA. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Curr Opin Investig Drugs. 2009;10(6):597-605.
49. Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol. 2009; 6(9):507-518.
50. Bruns CJ, Liu W, Davis DW, et al. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer. 2000;89(3):488-499.
51. Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 1999;59(20):5209-5218.
52. Eli Lilly and Company/ImClone LLC. A randomized, double-blind, mul-ticenter phase 3 study of irinotecan, folinic acid, and 5-fuorouracil (FOL-FIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progressive during or following frst-line combination therapy with bevacizumab, oxaliplatin, and a fuoropyrimidine. In: ClinicalTrials. gov [website on the internet]. Bethesda, MD: US National Library of Medicine; 2012. Available from: http://clinicaltrials.gov/show/NCT01183780. NLM identifer: NCT01183780. Accessed April 26, 2013.
53. National Cancer Institute (NCI): A randomized phase II study of irinotecan and cetuximab with or without the anti-angiogenic antibody, ramucirumab (IMC-1121B), in advanced, K-ras wild-type colorectal cancer following progression on bevacizumab-containing chemotherapy.). In: ClinicalTrials. gov [website on the internet]. Bethesda, MD: US National Library of Medicine; 2012. Available from: http://clinicaltrials.gov/show/NCT01079780. NLM identifer: NCT01079780. Accessed April 26, 2013.
54. ImClone LLC. An open-label, multicenter, randomized phase 2 study evaluating the safety and efficacy of 5 FU/FA and oxaliplatin (modifed FOLFOX 6) in combination with IMC-1121B or IMC-18F1 or without investigational therapy as second line therapy in patients with metastatic colorectal cancer following disease progression on frst line irinotecan-based therapy. In: ClinicalTrials.gov [website on the internet]. Bethesda, MD: US National Library of Medicine; 2012. Available from: http://clinicaltrials.gov/show/NCT01111604. NLM identifer: NCT01111604. Accessed April 26, 2013.
55. Grothey A, Tabernero J, Rougier P, et al. A randomized, double-blind, phase (Ph) III study of the irinotecan-based chemotherapy FOLFIRI plus ramucirumab (RAM) or placebo (PL) in patients (pts) with meta-static colorectal carcinoma (mCRC) progressive during or following frst-line therapy with bevacizumab (BEV), oxaliplatin (OXALI), and a fuoropyrimidine (FP) (RAISE) (NCT01183780). J Clin Oncol. 2012;30(Suppl):Abstract TPS3634.
56. Schwartz JD, Rowinsky EK, Youssoufan H, Pytowski B, Wu Y. Vascular endothelial growth factor receptor-1 in human cancer: concise review and rationale for development of IMC-18F1 (human antibody targeting vascular endothelial growth factor receptor-1). Cancer. 2010; 116(Suppl 4):1027-1032.
57. Wu Y, Zhong Z, Huber J, et al. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clin Cancer Res. 2006;12(21):6573-6584.
58. Bhargava P, Robinson MO. Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Curr Oncol Rep. 2011;13(2): 103-111.
59. Ivy S P, Wick J Y, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol. 2009;6(10):569-579.
60. Pfzer. A randomized, phase 2 study of FOLFOX Or FOLFIRI with AG-013736 or bevacizumab (Avastin) in patients with metastatic col-orectal cancer after failure of an irinotecan or oxaliplatin-containing frst-line regimen. In: ClinicalTrials.gov [website on the internet]. Bethesda, MD: US National Library of Medicine; 2011. Available from: http://clinicaltrials.gov/ct2/show/NCT00615056. NLM identifer: NCT00615056. Accessed April 26, 2013.
61. Pfzer. A phase II trial of single agent axitinib as maintenance therapy for patients with frst line metastatic colorectal cancer (mCRC). In: Clinical-Trials.gov [website on the internet]. Bethesda, MD: US National Library of Medicine; 2011. Available from: http://www.clinicaltrials.gov/ct2/ show/NCT01490866. NLM identifer: NCT01490866. Accessed April 26, 2013.
62. Boehringer Ingelheim Pharmaceuticals. A phase I-II study of BIBF 1120 and FOLFOX compared to bevacizumab and FOLFOX in frst line metastatic colorectal cancer patients. In: ClinicalTrials. gov [website on the internet]. Bethesda, MD: US National Library of Medicine; 2011. Available from: http://clinicaltrials.gov/show/NCT00904839. NLM identifer: NCT00904839. Accessed April 26, 2013.
63. NCIC Clinical Trials Group. A phase III randomized study of Brivanib Alaninate (BMS-582664) in combination with cetuximab (Erbitux®) versus placebo in combination with cetuximab (Erbitux®) in patients with K-RAS wild type tumors previously treated with combination chemotherapy for metastatic colorectal carcinoma. In: ClinicalTrials.gov [website on the internet]. Bethesda, MD: US National Library of Medicine; 2013. Available from: http://clini-caltrials.gov/show/NCT00640471. NLM identifier: NCT00640471. Accessed April 26, 2013.
64. AstraZeneca. A randomised, double-blind, multicentre phase II/III study to compare the efficacy of Cediranib (RECENTIN™, AZD2171) in combination with 5-fuorouracil, leucovorin, and oxaliplatin (FOLFOX), to the efficacy of bevacizumab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (HORIZON III). In: ClinicalTrials.gov [website on the internet]. Bethesda, MD: US National Library of Medicine; 2013. Available from: http://clinicaltrials.gov/show/NCT00384176. NLM identifer: NCT00384176. Accessed April 26, 2013.
65. Pfzer. A multicenter, randomised, double-blind, phase 3 study of sunitinib in metastatic colorectal cancer patients receiving irinotecan, 5-fuorouracil and leucovorin (FOLFIRI) as first line treatment. In: ClinicalTrials.gov [website on the internet]. Bethesda, MD: US National Library of Medicine; 2013. Available from: http://clinicaltrials.gov/ show/NCT00457691. NLM identifer: NCT00457691. Accessed April 26, 2013.
66. AIO-Studien-gGmbH. A controlled randomized double-blind multi-center phase II study of FOLFOX6 or FOLFIRI combined with sorafenib versus placebo in second-line metastatic colorectal carcinoma. In: ClinicalTrials.gov [website on the internet]. Bethesda, MD: US National Library of Medicine; 2013. Available from: http://www.clini-caltrials.gov/ct2/show/NCT00889343. NLM identifer: NCT00889343. Accessed April 26, 2013.
67. Bayer. A randomized, double-blind, placebo-controlled phase III study of regorafenib plus BSC versus placebo plus BSC in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy. In: ClinicalTrials.gov [website on the internet]. Bethesda, MD: US National Library of Medicine; 2013. Available from: http:// clinicaltrials.gov/show/NCT01103323. NLM identifer: NCT01103323. Accessed April 26, 2013.
68. Bayer. An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy (CONSIGN). In: ClinicalTrials.gov [website on the internet]. Bethesda, MD: US National Library of Medicine; 2013. Available from: http://clinicaltrials.gov/show/NCT01538680. NLM identifer: NCT01538680. Accessed April 26, 2013.
69. AstraZeneca. A phase II, double-blind, placebo controlled, randomized study to assess the efficacy and safety of 2 doses of ZD6474 (Vandetanib) in combination with FOLFOX vs FOLFOX alone for the treatment of colorectal cancer in patients who have failed therapy with an irinotecan and fuoropyrimidine regimen. In: ClinicalTrials. gov [website on the internet]. Bethesda, MD: US National Library of Medicine; 2013. Available from: http://clinicaltrials.gov/show/ NCT00500292. NLMidentifer:NCT00500292. Accessed April 26, 2013.
70. AstraZeneca. A phase II, double blind, placebo controlled, randomised study to assess the efficacy and safety of 2 doses of ZACTIMA™(ZD6474) in combination with FOLFIRI vs FOLFIRI alone for the treatment of colorectal cancer in patients who have failed therapy with anoxaliplatin and fuoropyrimidine containing regimen. In: ClinicalTrials.gov [website on the internet]. Bethesda, MD: US National Library of Medicine; 2011. Available from: http://clinicaltrials.gov/ show/NCT00454116. NLM identifer: NCT00454116. Accessed April 26, 2013.
71. Stivarga® (regorafenib) [prescribing information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; 2013.
72. Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129(1):245-255.
73. Grothey A, Van Cutsem E, Sobrero A, et al; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303-312.
74. Rudge JS, Holash J, Hylton D, et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting effcacious angiogenic blockade. Proc Natl Acad Sci U S A. 2007;104(47):18363-18370.
75. Sobrero A, Ackland S, Clarke S, et al; AVIRI Trial investigators. Phase IV study of bevacizumab in combination with infusional fuorouracil, leucovorin and irinotecan (FOLFIRI) in frst-line metastatic colorectal cancer. Oncology. 2009;77(2):113-119.
76. Narayana A, Gruber D, Kunnakkat S, et al. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg. 2012;116(2):341-345.
77. Chinot OL, de La Motte Rouge T, Moore N, et al. AVAglio: phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther. 2011;28(4): 334-340.
78. Kelly WK, Halabi S, Carducci M, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012;30(13): 1534-1540.
79. Sanofi/Regeneron. Sanofi and Regeneron Announce Regulatory and Clinical Update for Zaltrap® (aflibercept) [press release]. Paris: Sanof/Tarrytown, NY: Regeneron; April 5, 2012; Available from: http://en.sanofi.com/Images/30138_20120405_ZALTRAP_BLA_ VENICE_en.pdf. Accessed November 30, 2012.
80. National Cancer Institute (NCI). Phase II single arm trial of VEGF trap in patients with recurrent temozolomide-resistant malignant gliomas. In: ClinicalTrials.gov [website on the internet]. Bethesda, MD: US National Library of Medicine. Available from: http://clinicaltrials.gov/ show/NCT00369590. NLM identifer:NCT00369590. Accessed April 26, 2013.
81. National Cancer Institute (NCI)/ImClone LLC. An open label, phase 2 study evaluating the safety and efficacy of IMC-3G3 or IMC-1121B in patients with recurrent glioblastoma multiforme. In: ClinicalTrials. gov [website on the internet]. Bethesda, MD: US National Library of Medicine. Available from: http://clinicaltrials.gov/show/NCT00895180. NLM identifer:NCT00895180. Accessed April 26, 2013.
82. ImClone LLC. A phase 2, multicenter, randomized study of IMC-A12 or IMC-1121B plus mitoxantrone and prednisone in metastatic androgen-independent prostate cancer (AIPC) following disease progression on docetaxel-based chemotherapy. In: ClinicalTrials.gov [website on the internet]. Bethesda, MD: US National Library of Medicine. Available from: http://clinicaltrials.gov/show/NCT00683475. NLM identifer:NCT00683475. Accessed April 26, 2013.
83. Zoppoli G, Ferrando V, Scabini S. On biomarkers and pathways in rectal cancer: What's the target? World J Gastrointest Surg. 2012;4(12): 275-277.
84. Ballestrero A, Garuti A, Cirmena G, et al. Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond. Curr Cancer Drug Targets. 2012;12(4): 316-328.